×

NIH funds $945 million in research to tackle the national opioid crisis through NIH HEAL Initiative

Posted on October 11, 2019

Approximately 375 awards in 41 states will accelerate scientific solutions.

To reverse the opioid crisis that continues to grip the nation, the National Institutes of Health has awarded $945 million in total fiscal year 2019 funding for grants, contracts and cooperative agreements across 41 states through the Helping to End Addiction Long-term Initiative or NIH HEAL Initiative. The trans-NIH research effort aims to improve treatments for chronic pain, curb the rates of opioid use disorder (OUD) and overdose and achieve long-term recovery from opioid addiction.

In 2016, an estimated 50 million U.S. adults suffered from chronic pain and in 2018, an estimated 10.3 million people 12 years and older in the United States misused opioids, including heroin.

“President Trump’s approach to the opioid crisis and HHS’s strategy have both been based in the best science we have,” said HHS Secretary Alex Azar. “We have effective tools, such as medication-assisted treatment, but we still need better ways to treat opioid addiction and manage pain in an effective, personalized way. This historic investment by NIH was made possible by funding secured from Congress by President Trump, and will support our work in the current crisis and lay the work for a healthier future.”

The NIH HEAL Initiative is leveraging expertise from almost every NIH institute and center to approach the crisis from all angles and disciplines, and across the full spectrum of research from basic to implementation science in the areas of:

  • --Translation of research to practice for the treatment of opioid addiction

  • --New strategies to prevent and treat opioid addiction

  • --Enhanced outcomes for infants and children exposed to opioids

  • --Novel medication options for opioid use disorder and overdose

    --Clinical research in pain management

    --Preclinical and translational research in pain management

“It’s clear that a multi-pronged scientific approach is needed to reduce the risks of opioids, accelerate development of effective non-opioid therapies for pain and provide more flexible and effective options for treating addiction to opioids,” said NIH Director Francis S. Collins, M.D., Ph.D., who launched the initiative in early 2018. “This unprecedented investment in the NIH HEAL Initiative demonstrates the commitment to reversing this devastating crisis.”

The initiative will address multiple problems that are slowing or preventing progress on addressing the crisis, including:

Problem: Many people with OUD do not receive appropriate treatment for their disorder.

Scientific solution: The HEALing Communities Study and Justice Community Opioid Innovation Network (JCOIN) will integrate evidence-based interventions into community, justice and emergency room settings where people with OUD seek help. NIH will study which interventions or combination of interventions work best in which communities and implement them.

Problem: Many patients who receive medications for OUD do not stay on treatment long enough to achieve long-term recovery.

Scientific solution: NIH HEAL Initiative awards target novel, longer-lasting and innovative treatments for OUD. This includes using immunotherapies to prevent relapse and overdose, extended-release formulations and reducing drug cravings to give patients more options to sustain their recovery.

Problem: There are different types of pain and people experience pain differently, but it is not known which treatments will work best for which patients.

Scientific solution: NIH HEAL Initiative research will advance our understanding of pain by identifying biomarkers, endpoints and signatures of pain conditions, as well as providing evidence-based non-addictive treatments for discrete pain conditions such as back painpost-surgical pain and pain in hemodialysis patients.

Problem: Clinicians need to ensure that their patients’ pain is under control while also balancing the risks of long-term opioid therapy.

Scientific solution: The initiative will develop non-addictive medications for pain and test new models of care in real world settings. This includes a controlled trial of acupuncture for chronic low back pain, with NIH working with the Centers for Medicare & Medicaid Services to inform coverage determinations.

Problem: There is no national standard for care of infants born exposed to opioids.

Scientific solution: Research through the NIH HEAL Initiative will inform treatment guidelines for clinical care of infants who are exposed to opioids in the womb. Long-term studies of these infants will improve our understanding of pre- and post-natal opioid exposure on brain growth and development.  

“We need to ensure that people with chronic pain have effective treatment options that don’t expose them to the risk of opioids,” said Rebecca G. Baker, Ph.D., director, NIH HEAL Initiative. “Preventing opioid misuse and addiction through enhanced pain management and improving treatments for OUD and addiction are both critical parts of our trans-NIH response to the opioid crisis.”

Learn more about the NIH HEAL Initiative programs and awards, and the opioid crisis.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.







Tokuyama Empowers Donates More Than $18,000 Worth of Products to Homeless Not Toothless

Posted on October 10, 2019

Tokuyama Empowers, Tokuyama Dental America’s corporate social responsibility program, is proud to donate more than $18,000 of dental products to Homeless Not Toothless. The nonprofit is committed to raising the pride and dignity of underserved children through quality and compassionate dental services. In particular, the focus of Homeless Not Toothless is on foster children; children living below the poverty line, in low-income areas, without insurance benefits.

With the donated products from Tokuyama Dental, Homeless Not Toothless will provide dental care to thousands of underserved children in the South Los Angeles area. South Los Angeles, Boyle Heights and Watts has been recognized as a low-income suburban area with lower educational attainment within its catchment (California Community Foundation). Dental care is lacking in this area and residents live below the poverty line.

With dental issues being the number one reason for absenteeism, Homeless Not Toothless is one solution to ensure children get to school and receive an education. Children who do not receive proper dental care are more likely to miss school than those who have preventative dental services.  The U.S. Department of Health and Human Services estimates 51 million school hours are lost per year because of dental related illness, and children from lower income families are 12 times more likely to miss school due to dental problems.

“Underserved children face significant barriers to dental care. We are happy to partner with Homeless Not Toothless to address unmet dental needs that are hindering children from achieving their full potential.” said Masa Ogata, CEO of Tokuyama Dental America. 

Tokuyama Empowers, Tokuyama Dental America’s corporate social responsibility program, strives to increase access to dental care for underserved and uninsured populations by collaborating with nonprofits, free clinics, national and local associations, and volunteer dentists. Tokuyama Empowers supports its partners through product donations, enabling low-income people to receive the care they need to improve their health and quality of life.  

For more information, please contact Anna Mai at anna.mai@tokuyama-us.comor 1-877-378-3548.







Whip Mix Receives Philanthropist Award

Posted on October 10, 2019

Whip Mix Corporation was awarded the Corporate Philanthropist Award by Partners in Philanthropy, Louisville Business First's annual salute to local companies’ generosity and community service endeavors. Whip Mix was honored based on cash awards as well as volunteer hours to organizations including Metro United Way, Library Foundation, and the University Of Louisville School Of Dentistry. Allen Steinbock, CEO, accepted the award on behalf of Whip Mix at the ceremony.

 

 







JOMS study: Facial injuries less likely to occur in bicyclists who wear helmets

Posted on October 10, 2019

Bicyclists who wear helmets are less likely to experience a facial injury in a bicycle crash, according to a study in the October issue of the Journal of Oral and Maxillofacial Surgery, the official journal of the American Association of Oral and Maxillofacial Surgeons (AAOMS).

However, among bicyclists who sustained a facial injury, severity did not significantly differ between those who wore helmets and those who did not – possibly because standard bicycle helmets lack a mask to protect the face, researchers from the University of Washington wrote.

The retrospective cohort study involved 1,379 bicyclists who were injured during a six-year span and went to a medical center for evaluation and treatment. Most of the bicyclists (60.6 percent) wore a helmet. Researchers found those who wore helmets were 40 percent less likely to experience a facial injury from a crash; 30.6 percent of those not wearing a helmet were injured compared to 17.3 percent of bicyclists wearing a helmet.

Researchers used the Face Abbreviated Injury Scale (FAIS) to determine injury severity. A score of zero is no injury, and a maximum score of four is severe. The study found no statistically significant difference between the average FAIS scores for helmeted and non-helmeted bicyclists.

"Further research is needed as more people use bicycles in their everyday commute," researchers wrote. "With more bicycle share options, the need for helmet regulations and changing attitudes on environmental impact, we should anticipate changes in injury patterns, frequency and severity."

According to the study results, men were less likely to wear a helmet, and non-helmeted bicyclists were younger than helmeted bicyclists. In addition, alcohol use was less frequently reported among helmeted bicyclists, and bicyclists with alcohol detected in their system when injured had a twofold higher risk of facial injuries.

The study notes that some bicyclists were injured while mountain biking, and mountain bike helmets provide more facial protection than standard bicycle helmets.

"We advocate for the implementation of a protective chin strap to help prevent lower face injuries like other studies, a redesign of bicycle helmets to provide facial protection and a limit on the blood alcohol concentration of bicyclists," researchers wrote.

No states require bicyclists to wear helmets, and 21 states have regulations that apply to minors, the study added.

"Legislation requiring helmet use might increase compliance," researchers wrote. "However, enforcing helmet laws to increase helmet compliance might not substantially decrease maxillofacial injury severity, as shown in the present study, especially because many factors can affect helmet compliance and injury severity."

The authors of "Helmets Decrease Risk of Bicyclist-Related Maxillofacial Injuries But Not Severity" are from the University of Washington School of Dentistry: Marcus J. Hwang; Jasjit K. Dillon, DDS, MBBS, FDSRCS, FACS; and Thomas B. Dodson, DMD, MPH, FACS.

The full article can be accessed at JOMS.org/article/S0278-2391(19)30449-5/fulltext.

The Journal of Oral and Maxillofacial Surgery is published by the American Association of Oral and Maxillofacial Surgeons to present to the dental and medical communities comprehensive coverage of new techniques, important developments and innovative ideas in oral and maxillofacial surgery. Practice-applicable articles help develop the methods used to handle dentoalveolar surgery, facial injuries and deformities, TMJ disorders, oral and head and neck cancer, jaw reconstruction, anesthesia and analgesia. The journal also includes specifics on new instruments and diagnostic equipment, and modern therapeutic drugs and devices.

The experts in face, mouth and jaw surgery® — The American Association of Oral and Maxillofacial Surgeons (AAOMS) is the professional organization representing more than 11,000 oral and maxillofacial surgeons, OMS residents and OMS professional staff in the United States. AAOMS supports its fellows' and members' ability to practice their specialty through education, research and advocacy. AAOMS fellows and members comply with rigorous continuing education requirements and submit to periodic office anesthesia evaluations. For additional information about oral and maxillofacial surgery, visit the AAOMS websites at AAOMS.org and MyOMS.org.

SOURCE American Association of Oral & Maxillofacial Surgeons







Henry M. Goldman School of Dental Medicine becomes first U.S. dental school to acquire, implement robotic-assisted surgery

Posted on October 9, 2019

Boston University’s Henry M. Goldman School of Dental Medicine (GSDM) announced today that they have become the first U.S. dental school to acquire, install, and use two surgical robotic devices for dental implant surgeries.

These devices will provide an opportunity for the School’s predoctoral students and postdoctoral residents to learn how state-of-the-art robotic technology, with its accuracy and precision during dental surgery, can augment and enhance clinical practice and patient care.

The robot-assisted surgical device, known as Yomi, was developed by Miami-based healthcare start-up Neocis. It is the first (and to date, only) such device cleared by the U.S. Food and Drug Administration for dental implant surgery.

“This technology is truly revolutionary and will change – and improve – the way we approach dental implant surgeries at the Henry M. Goldman School of Dental Medicine,” said Dr. Alexander Bendayan, GSDM’s assistant dean of digital development & clinical training. “Introducing this advanced technology to our patient treatment centers will ensure that our predoctoral students and postdoctoral residents are prepared to be leaders in the field and will help to establish new standards of care for the profession.”

Using the Yomi system, the provider performing the surgical procedure first creates a virtual plan for the placement of a dental implant using detailed 3D scans of the patient’s mouth. The system then uses physical cues to guide the provider along the precise implementation of that plan – but is also able to adjust dynamically to accommodate mid-procedure changes. Yomi augments a provider’s ‘feel,’ giving real-time feedback via haptic technology to guide a provider along the treatment plan. But the provider controls the handpiece at all times: By design, the Yomi system complements, rather than overrides, a provider’s clinical expertise.

“We believe that Yomi may become a new standard of care for dental implants, and are thrilled to be working alongside the faculty, students, and residents at GSDM to implement this technology,” said Dr. Alon Mozes. “By embedding the technology at the dental-school level, we are building comfort and skill with this technology from the ground up.”

The School, with the assistance of trained technicians from Neocis, completed installing and calibrating the robotic devices in late September. GSDM faculty members participated in a rigorous two-day trainings on the Yomi system on September 25-26, 2019; additional two-day trainings will be held throughout October, and November. Once trained, faculty members will use the Yomi system on their own patients and will also instruct GSDM predoctoral students and postdoctoral residents on the technology. Neocis will provide ongoing service and support.

With the acquisition of Yomi, GSDM continues its commitment to pioneering new dental technologies in its predoctoral and postdoctoral educational programs. In 2015, GSDM became the first dental school in the U.S. to implement CAD/CAM guided dental implant surgery, first using CEREC and SICAT guides and then, in 2018, introducing Nobel Biocare guides. All predoctoral students at GSDM currently have the opportunity to place a dental implant using guided surgery – a rarity for U.S. predoctoral dental programs – and soon will be able to also gain experience using the first robot-assisted dental surgical system in the U.S.

“At the Henry M. Goldman School of Dental Medicine, innovation is more than a buzz word: It’s a mindset,” said Dr. Jeffrey W. Hutter, dean and Spencer N. Frankl professor in dental medicine. “Our School has always been a leader in embracing cutting-edge dental technologies, and I am proud to continue that tradition of innovation with Yomi.”

About Boston University Henry M. Goldman School of Dental Medicine: Founded in 1963, the Boston University Henry M. Goldman School of Dental Medicine is the premier academic dental institution promoting excellence in dental education, research, oral health care, and community service to improve the overall health of the global population. With a faculty of more than 240 educators, clinicians, and researchers and more than 250 staff members, the School offers a full spectrum of predoctoral and postdoctoral education programs and a complete range of graduate programs and degrees to more than 700 students.

About Neocis, Inc.: Neocis® is a private company located in Miami, Florida, that is transforming dental implant surgery with advanced robotics, with a vision of advancing healthcare through the latest technology. The company's FDA cleared Neocis Guidance System, or Yomi®, is indicated for use to provide assistance in both the planning (pre-operative) and the surgical (intra-operative) phases of dental implantation surgery. The system provides software to preoperatively plan dental implantation procedures and provides navigational guidance of the surgical instruments. Yomi® provides surgical guidance through the use of haptic robotic technology, software, and multisensory feedback to help achieve the right position, angulation, and depth to place the implant exactly according to plan. Yomi® enables a minimally invasive flapless approach, which has been proven to lead to faster surgery, faster recovery, and less pain for the patient. Learn more at www.neocis.com.







Whip Mix Presents 8th Annual Digital Forum

Posted on October 9, 2019

On October 4-5, 2019, Whip Mix presented its 8th annual Digital Forum entitled "Digital Excellence: Our Vision, Your Future." The event, which was co-sponsored by the Kentucky Dental Lab Association, featured some of today's in-demand speakers and topics that are burning up the Dental Forums, dental social media pages, and dental/lab journals.

Speakers included Dr. Ed McLaren, speaking on today’s state-of-the-art zirconia materials; Bennett Napier, of the NADL, talking about how times are changing; Mark Williamson, CDT, who demonstrated characterization techniques for 3D printed dentures; Sevan Pulurian, who took everyone on a journey through 3Shape software; Gary Morgan, covering FDA Compliance; Bart Hyde, CDT and Dr. Brandon Stapleton, discussing cross-country lab-dentist communications with digital dentistry; Mike Webb, demonstrating CIM System’s CAM software; Nick Windlow of Smile Shapers, explaining the growth of aligner technology; Al Fillastre, showing the techniques necessary to create monolithic zirconia without adjusting it after sintering; and Cory Lambertson, presenting the step-by-step technique for producing 3D printed dentures.

The two-day experience featured vendors, a dinner with a very competitive game of trivia, and lots of camaraderie and networking.







BruxZir® Solid Zirconia Celebrates 10th Anniversary

Posted on October 8, 2019

Glidewell Dental announces historic milestone for No. 1 prescribed brand of monolithic zirconia

Glidewell Dental, an industry-leading provider of dental laboratory services and restorative materials, is celebrating the 10-year anniversary of the release of BruxZir® Solid Zirconia. Since its launch, BruxZir has become the No. 1 prescribed brand of monolithic zirconia and has been utilized around the globe to create more than 20 million beautiful smiles.

In recognition of this 10-year milestone, Glidewell is giving back to the dental practitioner for a decade of trust. To learn more, visit bruxzir.com.

“We are truly humbled that BruxZir has earned such widespread trust and is the only zirconia brand requested by name,” said President and CEO Jim Glidewell, CDT. “We originally developed BruxZir to give clinicians a tooth-colored alternative to cast gold restorations. Now BruxZir has become the leading, lasting and loved brand by dentists and patients around the world.”

When BruxZir Solid Zirconia launched in 2009, the brand was known as “more brawn than beauty” as it was primarily used in the posterior due to its fracture-resistant nature. Yet, the Glidewell Research & Development team was never satisfied. Over the past decade, the team continued innovating BruxZir zirconia and created enhanced formulations to address specific clinical needs. Now BruxZir is prescribed everywhere in the mouth for an expansive range of restorations, including crowns, bridges, veneers, screw-retained crowns, full-arch implant prostheses, inlays and onlays.

As this leading family of materials marks its 10th anniversary, BruxZir Solid Zirconia is available in two distinct formulations: BruxZir Full-Strength, which is engineered to withstand the toughest oral challenges, and the new BruxZir Esthetic. Since its release in 2018, BruxZir Esthetic has become widely adopted by dentists for its optimized combination of strength and translucency, a lifelike vitality engineered for the anterior and its enhanced shade matching for predictable results.

Throughout the years, practicing clinicians and product evaluators have given top marks to the material. In the August 2019 issue of Clinicians Report®, an independent publication, BruxZir Solid Zirconia was described as “the most successful tooth-colored restoration in the history of dentistry.”* The Clinicians Report also recognized BruxZir Full-Strength as "Best in Class" after an eight-year clinical performance study† revealed the following results:

--100% survival

--Zero terminal fractures

--Minimal wear on opposing dentition

When clinicians prescribe BruxZir restorations from Glidewell, not only do they receive a material that has undergone rigorous clinical research, but they also get a product that is fabricated with cutting-edge manufacturing, backed by a hassle-free warranty and serviced by a highly knowledgeable team of customer representatives. As the brand moves forward and goes beyond its decade of trust, Glidewell remains committed to providing dentists and patients alike with leading validation, lasting performance and loved results.

*An independent, nonprofit, dental education and product testing foundation, Clinicians Report®, August 2019. For the full report, go to bruxzir.com/most-successful.​

†An independent, nonprofit, dental education and product testing foundation, Clinicians Report®, November 2018. For the full report, go to bruxzir.com/8-year​. Study results apply to BruxZir 2009 3Y zirconia. ​







KaVo Kerr Introduces Take 1™ Hydro™ VPS Impression Material for Accurate First-Make Impressions

Posted on October 8, 2019


Featuring a host of innovations, Take 1 Hydro makes impressions to the next level of detail, accuracy, and simplicity.

KaVo Kerr unveils its next-generation VPS impression material for better-fitting restorations: Take 1™ Hydro™. Featuring one of the industry’s lowest contact angles at ≤10° on uncured material, Take 1 Hydro allows clinicians to push impression materials deeper into the sulcus to capture better margins and minute details, free of voids and distortions. This first-take accuracy reduces the need for time-consuming and costly re-dos, as well as patient frustration.

“For dentists, clinical staff, the laboratory, and patients alike, having to retake impressions or make adjustments because of flaws or ill-fitting restorations is a huge source of frustration,” explains Yoshita Chaudhri, Marketing Manager at KaVo Kerr. “With Take 1 Hydro VPS impression material, we’ve made it easier for clinicians to take accurate, detailed impressions on the very first try.”

In addition to the extremely low contact angle, Take 1 Hydro offers highly durable and elastic material that provides excellent dimensional stability. This minimizes shrinkage during handling and shipping, resulting in final crowns that better match the patient’s preparation. Take 1 Hydro also uses an advanced surfactant formula that breaks down moisture barriers between the preparation area and impression material. This excellent surface activation supports crowns that fit better and require fewer adjustments, preventing wasted time, schedule backups, and delays.  

With its many advancements, Take 1 Hydro is the future-proof VPS solution for today’s digitally driven practices. “Digital scans do the job for most impressions, but certain situations need the deeper reach of a VPS impression material,” says Yoshita. “Take 1 Hydro’s deep reach allows material to render details below the gingival tissues that digital scans can’t always see. So doctors can get the full picture for better-fitting restorations, on the first take.”

“We recognize that no two intraoral situations are alike, and different doctors have different preferences,” adds Kim Dyer, Director of Product Management at KaVo Kerr. “To meet those varying needs, Take 1 Hydro offers a curated selection that simplifies the doctor’s choices.” These include regular and fast set times, and options ideal for challenging intraoral situations such as full or partial edentulous impressions, full arch restorations, as well as single- and multi-unit applications. For the ultimate moisture displacement and accuracy, dentists are recommended to combine Take 1 Hydro with KaVo Kerr’s versatile Take 1 Retraction paste, which also launched earlier this year.

To learn more about Take 1 Hydro, visit kerrdental.com or contact KaVo Kerr at 800-KERR123.

About KaVo Kerr

KaVo Kerr is a premier dental solutions provider committed to exceptional customer experience.  Established in 2016, KaVo Kerr combines two global leaders with a long history of innovation and commitment to Dental Excellence and a common purpose of enabling healthy, beautiful smiles.  The KaVo Kerr portfolio of dental diagnosis and treatment solutions includes restoratives, digital imaging solutions, treatment units, rotary instruments, laboratory equipment, infection prevention and practice education. For more information, visit www.KaVoKerr.com, like us at www.Facebook.com/KaVoKerr, and follow us at www.Instagram.com/kavokerr.







Planmeca USA Appoints Rudy Wolf as Director of Sales, Strategic Accounts

Posted on October 8, 2019

Hoffman Estates, Ill. (October 8, 2019) –Planmeca USA, a leading manufacturer of dental imaging and CAD/CAM equipment, today announced that Rudy Wolf has joined the company as Director of Sales, Strategic Accounts. Wolf brings a wealth of knowledge in the dental industry, having held various roles over the last 15 years.

Wolf recently served as zone general manager at Henry Schein Dental providing the direction and management of all phases of field sales and operations for the Atlantic Coast.

“Rudy has an innate ability to nurture key relationships with both his fellow team members and customers,” said Glen Kendrick, Vice President of Sales, Planmeca USA. “His proven techniques and discipline to build strategic partnerships are invaluable as we continue to support the growing non-private practice market segment.”

At Planmeca USA, Wolf plans to use his expertise to implement long-term planning and sales growth initiatives for the group practice and Dental Service Organizations markets, as well as community and government health centers.

“I am excited to be working for a company with such a strong heritage and a clear vision for the future,” stated Wolf. “Our motto says it all, ‘Better care through innovation.' Our solution helps our customers provide superior dental care while simultaneously improving efficiency and practice profitability. Planmeca is a first-class organization with a full suite of imaging and chairside dentistry solutions, positioning us to provide solutions to one of the fastest-growing segments of dentistry.”

To learn more about Planmeca USA, visit www.planmeca.com/na.

About Planmeca USA:

Planmeca USA is a subsidiary of Planmeca, the largest privately held company in the dental equipment market and one of the industry’s leading manufacturers of dental X-rays and core equipment. With a North American office located in Hoffman Estates, Illinois, and international headquarters in Helsinki, Finland, Planmeca is well established in high-tech dental markets and currently serves 120 countries worldwide. For more information, visit planmecausa.com.







Clinician's Choice® Launches New Bluewave Soft Tissue Diode Laser: Versatility and Surgical Accuracy

Posted on October 7, 2019

As a global innovation leader for dental product solutions, Clinician’s Choice continues an impressive run of pioneering product introductions with Bluewave™ Soft Tissue Diode Laser, the desktop laser that redefines performance expectations. Bluewave is characterized by its intuitive operation, enhanced ergonomics, and high-contrast blue-aiming beam that provides greater visibility at the surgical site. It's also incredibly affordable.

“For those looking for a versatile soft tissue diode laser, Bluewave combines outstanding performance with a simplified set-up and operation,” stated Dr. Doug Harvey, “Whether performing more soft tissue procedures in-house or simply increasing the efficiency, comfort, and predictability of your restorative and periodontal techniques, the portable Bluewave laser delivers at a value no other laser can match.”

The Bluewave diode laser outperforms over a wide range of dental indications – from gingival contouring and tissue retraction for impression-taking to laser-assisted periodontal therapy – with greater patient comfort, faster healing times, and often with minimal need for anesthetic.

The 810 nm diode laser is engineered to make laser therapy truly convenient and expedient. Featuring a long-lasting lithium-ion battery, light-weight design, and wireless foot pedal, the Bluewave is truly portable and allows the clinician to move between operatories with ease. Three intuitive and easy-to-use settings simplify treatment protocols, with an additional custom setting for individual user’s preferences.

Bluewave is designed to make life easier for clinicians. Its unique blue-aiming beam produces higher contrast on oral tissues and blood than the traditional red beam for enhanced visibility and efficiency. The curved, ergonomic contours of the handpiece provide better posterior access in multiple positions, reducing hand fatigue during longer procedures. Disposable tips eliminate the inconvenience and inconsistency of strip-and-cleave systems.

“Clinician’s Choice is committed to providing clinically proven, time-saving solutions to dentists, globally” said Peter Jordan, President of Clinician’s Choice, “Laser-assisted restorative procedures and their impressive benefits to both clinicians and patients is inline with our commitment to better dentistry – making the new Bluewave Soft Tissue Diode Laser a natural transition for us.”

Clinician’s Choice will be unveiling Bluewave at the 2019 Greater New York Dental Meeting from December 1 – 4. Visitors at the Clinician’s Choice (#2515) or Henry Schein booth will get to discover its technical properties, numerous applications, and accessories for the Bluewave diode laser as well as have a hands-on opportunity to demo the Bluewave laser at the show.

For more information about the Bluewave Soft Tissue Diode Laser or to set up an in-office demonstration, clinicians can contact Henry Schein at 1-877-887-1211 or visit demo.clinicianschoice.com/bluewave

About CLINICIAN'S CHOICE DENTAL PRODUCTS, INC. 

For 25 years, CLINICIAN’S CHOICE DENTAL PRODUCTS INC. has been providing dentists throughout North America with clinically proven products and techniques designed to solve the everyday clinical challenges of their esthetic restorative procedures. The promotion of better dentistry forms the core of the company’s values and is demonstrated by an on-going commitment to the presentation of clinical seminars, workshops, and scientific research studies. 







© 2019 AEGIS Communications | Privacy Policy